Abstract:Abstract BACKGROUND AND AIMS Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease. It is caused by mutations in the PKD1 gene, and to a lesser extent PKD2. In this context, accumulating evidence has suggested a potential role of reduced AMP-activated protein kinase (AMPK) signaling in modulating cyst growth. We assessed the potential effects of PXL770, a clinical stage direct allosteric AMPK activator in conventional ADPKD models—3D cyst growth/swelling in vitro and efficacy in an ADPKD mouse model. METHOD In vitro, PXL770 (0.5–50 μM) was tested in 3D cyst assays using: (i) principal-like Madin-Darby Canine Kidney cells (plMDCK) activated by forskolin 10 μM and (ii) ADPKD patient-derived primary cells activated by desmopressin 2.5 μM. In both assays AMPK activation was also assessed by western blotting. In vivo, a kidney specific P18 tamoxifen induced Pkd1 KO mouse model (KspCad-CreERT2, Pkd1lox, lox—‘ADPKD mice’ [Lantinga-van Leeuwen IS, Hum Mol Genet 2007]) was used. Following Pkd1 inactivation at age 18–20 days, mice (n = 22 per group) received PXL770 75 mg/kg by oral gavage twice daily from 42 to 103 days old of age. Mice were treated until 50% of the untreated ADPKD group showed renal failure (blood urea level ≥20 mmol/L). Kidney weight and kidney histology were evaluated. RESULTS In plMDCK cysts, PXL770 dose dependently reduced cyst growth induced by forskolin by 30%, 65% and 82% at 10, 25 and 50 μM, respectively, compared with untreated control cysts (P < 0.05). These results were confirmed in human cysts where PXL770 inhibited desmopressin induced cyst swelling measured by cyst area, −67% at 15 μM compared with untreated control cysts (P < 0.001), and −115% at 50 μM (P < 0.0001)—below cyst area observed in solvent unstimulated condition. Similar result was achieved with tolvaptan. PXL770-mediated AMPK activation was confirmed in both cyst assay systems. Untreated ADPKD mice exhibited a significantly elevated level of blood urea compared with wild-type mice (+105%, P < 0.01). The blood urea level was lowered in PXL770-treated mice compared with untreated animals (−47%, P < 0.01). PXL770 significantly reduced total kidney weight (−29%, P < 0.01) and total kidney to body weight ratio (−35%, P < 0.01) compared with untreated ADPKD mice, without modifying the body weight. Untreated ADPKD mice demonstrated extensive renal epithelial cyst formation, with a cystic area and a cystic index of 9.4 mm2 and 33%, respectively. In PXL770-treated ADPKD mice, the mean cystic area and the cystic index were lowered to 7.1 mm2 and 28%, respectively. CONCLUSION Direct AMPK activation with PXL770 strongly reduced cyst growth and swelling in vitro in canine and human models and was shown to produce considerable efficacy in an orthologous genetic mouse model of ADPKD. These results show the potential of direct allosteric AMPK activation in ADPKD and support the further development of PXL770 in this indication.

Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy

MO019: Preclinical Efficacy of Direct AMPK Activation with a Novel Small Molecule–PXL770–For the Treatment of Autosomal Dominant Polycystic Kidney Disease

Elovl1 inhibition reduced very long chain fatty acids in a mouse model of adrenoleukodystrophy

Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy

Drug discovery for X-linked adrenoleukodystrophy: An unbiased screen for compounds that lower very long-chain fatty acids

From gene to therapy: a review of deciphering the role of ABCD1 in combating X-Linked adrenoleukodystrophy

Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy

Antioxidant Response in Human X-Linked Adrenoleukodystrophy Fibroblasts

Intracerebral lentiviral ABCD1 gene therapy in an early disease onset ALD mouse model

Generating human AMN and cALD iPSC-derived astrocytes with potential for modeling X-linked adrenoleukodystrophy phenotypes

Lipidomic biomarkers in plasma correlate with disease severity in adrenoleukodystrophy

ABCD2 is a direct target of β-catenin and TCF-4: implications for X-linked adrenoleukodystrophy therapy

Nervonic Acid Attenuates Accumulation of Very Long-Chain Fatty Acids and is a Potential Therapy for Adrenoleukodystrophy

Multi-Omic Approach to Identify Phenotypic Modifiers Underlying Cerebral Demyelination in X-Linked Adrenoleukodystrophy

In vivo adenine base editing rescues adrenoleukodystrophy in a humanized mouse model

Discovery of Novel, Orally Bioavailable Pyrimidine Ether-Based Inhibitors of ELOVL1

Modeling and rescue of defective blood-brain barrier function of induced brain microvascular endothelial cells from childhood cerebral adrenoleukodystrophy patients

AMPK-activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching

Polymeric nanoparticles delivery of AMPK activator 991 prevents its toxicity and improves muscle homeostasis in Duchenne Muscular Dystrophy

Two Single Nucleotide Deletions in the ABCD1 Gene Causing Distinct Phenotypes of X-Linked Adrenoleukodystrophy

Role of ACSBG1 in Brain Lipid Metabolism and X-Linked Adrenoleukodystrophy Pathogenesis: Insights from a Knockout Mouse Model